The economic value of insulin glargine 300 U/mL (Gla-300) in people ≥18 years of age with type 2 diabetes mellitus: a value-based economic model from a U.S. payer perspective

Figures & data

Figure 1. Framework of budget impact model.

Gla-300: Insulin Glargine 300 U/mL; HCRU: Healthcare Resource Utilization, PPPY: Per Patient Per Year; PwT2D: Patients with Type 2 Diabetes.

Figure 2. Patient type flowchart.

PwT2D: Patients with Type 2 Diabetes.

Table 1. Potential scenarios and their description.

Scenarios	Description
1	Use of net costs of drugs instead of wholesale acquisition cost (WAC)
2	Alternative market utilization assumptions over projected years for longer-acting BIs
3	Changing the projected market share of the longer-acting BIs to 100% market share by projected year 3 from the baseline market share of 8.00%

BIs: Basal Insulins.

Table 2. Market shares for base case and scenarios (in %).

	Base case				Scenario 2: Longer-acting to long-acting BIs switch				Scenario 3: All patients switching to longer-acting BIs by projected year 3
Insulin	Base-line	Year 1	Year 2	Year 3	Base-line	Year 1	Year 2	Year 3	Base-line	Year 1	Year 2	Year 3
Longer-acting BIs	8.00	7.57	6.95	6.74	8.00	8.43	9.05	9.26	8.00	50.00	100	100
Long-acting BIs	70.26	71.89	65.60	54.16	70.26	71.03	63.50	51.65	70.26	38.89	–	–
Glargine biosimilars for long-acting BIs	7.18	5.22	11.96	23.54	7.18	5.22	11.96	23.54	7.18	2.83	–	–
IDeg-100	14.56	15.31	15.49	15.55	14.56	15.31	15.49	15.55	14.56	8.28	–	–
Total	100	100	100	100	100	100	100	100	100	100	100	100

BIs: Basal Insulins; IDeg: Insulin Degludec.

Figure 3. Tornado diagram for base case.

BIs: Basal Insulins.

Figure 4. Number of targeted patients over time categorized by Sub-population.

Figure 5. Budget impact for PwT2D receiving basal insulins, PY ($).

PY: Per Year; T2D: Type 2 Diabetes; U.S.: United States.

Figure 6. Total costs in PwT2D receiving basal insulins, PPPY $ (by patient category).

PPPY: Per Patient Per Year; T2D: Type 2 Diabetes; U.S.: United States.

Figure 7. Total costs in PwT2D receiving basal insulins, PPPY $ (by specific HCRU event rates).

HCRU: Healthcare Resource Utilization; PPPY: Per Patient Per Year; T2D: Type 2 Diabetes; U.S.: United States.

Figure 8. Tornado diagram for scenario analysis.

BIs: Basal Insulins; WAC: Wholesale Acquisition Cost.

Table 3. Scenario results.

Scenario number	Scenario	Difference from Baseline, Total Costs per Patient in PwT2D receiving basal insulins, PY $
	Base case	$686
1	Net costs vs WAC (impact of treatment costs)	$593
2	Alternative market utilization assumptions over projected years for longer-acting BIs	$676
3	100% market share to longer-acting BIs by projected year 3	-$660

BIs: Basal Insulins; PY: Per Year; T2D: Type 2 Diabetes; WAC: Wholesale Acquisition Cost.